CXCR2 and breast cancer: For example, the silencing of the CXCR2 receptor in murine mammary tumor cells was shown to enhance antitumor activity of paclitaxel in vivo [47], and inhibition of CXCR2-mediated signaling in human colon cancer lines was shown to reduce cell migration and invasion while enhancing the tumor response to oxaliplatin [48].